Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. (VRCA) reported that Interim CFO John J. Kirby purchased common stock in the open market. On 2026-08-18, he bought 5,000 shares at a weighted average price of $4.93 per share, in multiple trades priced between $4.85 and $4.99. After this transaction, he directly owns 23,962 shares of Verrica common stock.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider Kirby John J.

Role Interim CFO

Bought 5,000 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	5,000	$4.93	$25K

Holdings After Transaction: Common Stock — 23,962 shares (Direct)

Footnotes (1)

1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 5,000 shares Weighted average purchase price: $4.93 per share Trade price range: $4.85–$4.99 per share +3 more

6 metrics

Shares purchased 5,000 shares Common Stock bought by Interim CFO on 2026-08-18

Weighted average purchase price $4.93 per share Average price for the 5,000-share purchase on 2026-08-18

Trade price range $4.85–$4.99 per share Range of prices for multiple trades included in the 5,000-share purchase

Shares owned after transaction 23,962 shares Direct ownership of John J. Kirby following the reported purchase

Net buy shares 5,000 shares Net share change across all transactions in this Form 4

Buy transactions count 1 Number of reported buy transactions in this Form 4

Key Terms

weighted average price, open market or private transaction, direct ownership

3 terms

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction_code_description: Purchase in open market or private transaction"

direct ownership financial

"total_shares_following_transaction ... direct_or_indirect: D"

FAQ

What insider transaction did VRCA report for Interim CFO John J. Kirby?

Interim CFO John J. Kirby purchased 5,000 VRCA common shares on 2026-08-18. The shares were bought in the open market at a weighted average price of $4.93 per share, across multiple trades between $4.85 and $4.99.

At what price did the VRCA insider buy shares on 2026-08-18?

John J. Kirby bought VRCA shares at a weighted average price of $4.93 per share. According to the disclosure, individual trades occurred at prices ranging from $4.85 to $4.99, inclusive, in open-market transactions.

How many VRCA shares does Interim CFO John J. Kirby own after this Form 4 transaction?

After the reported purchase, John J. Kirby directly owns 23,962 shares of Verrica Pharmaceuticals common stock. This reflects the addition of 5,000 shares acquired in the 2026-08-18 open-market transaction disclosed in the Form 4.

Was the 2026-08-18 VRCA insider transaction under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not selected, so the reported 5,000-share VRCA purchase by John J. Kirby on 2026-08-18 is not affirmed as executed pursuant to a Rule 10b5-1 trading plan.

What type of transaction did VRCA report in this Form 4 filing?

The Form 4 reports a purchase of common stock by Interim CFO John J. Kirby. It is coded as a “P” transaction, described as a purchase in an open market or private transaction, totaling 5,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 05:01 PM Accepted by SEC EDGAR 08/18/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirby John J.

(Last) (First) (Middle)

C/O VERRICA PHARMACEUTICALS INC.

44 W. GAY ST., SUITE 400

(Street)

WEST CHESTER PENNSYLVANIA 19380

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		P		5,000	A	$4.93(1)	23,962	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ John J. Kirby	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)